When it becomes an approved option, retatrutide may be offered as a triple agonist weight loss treatment within a supervised program
Serious side effects are rare but worth knowing about
GLP-1 receptor agonists are medications that mimic this hormones effect
Because of their effectiveness in treating obesity and diabetes, the WHO added GLP-1 therapies to its Essential Medicines List for managing type 2 diabetes in high-risk groups in September last year
To view digital features for this article go to Introduction Obesity (defined as a body mass index [BMI] 30 kg/m 2 in adults [1]) is a major health concern in the USA [2] and is associated with multiple complications, including cardiovascular disease, type 2 diabetes, and osteoarthritis [3,4,5,6,7,8]
Nearly identical assertions are also being pursued against other GLP-1 receptor agonists, such as Wegovy, Mounjaro, Rybelsus, Saxenda, and Trulicity